Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial

Reuters

2025/11/10

Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial

Day One Biopharmaceuticals Inc. has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582690873"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582690873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582690873?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582690873","market":"us","top_or_hot":-1,"title":"Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals Inc.</a> has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting &amp; Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDay One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals Inc.</a> has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting &amp; Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9Sxsb:1","article_id":"2582690873","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582690873","pubTimestamp":1762776121,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Day One Biopharmaceuticals Inc. has announced that new data on OJEMDA  will be presented at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology , taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma  with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-genera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","DAWN":"Day One Biopharmaceuticals Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股"},"translate_title":"Day One Biopharmaceuticals报告OJEMDA在儿童低级别神经胶质瘤试验中的持久反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"DAWN":0.9},"content_text":"Day One Biopharmaceuticals Reports Durable Responses With OJEMDA in Pediatric Low-Grade Glioma Trial\n    \n\nDay One Biopharmaceuticals Inc. has announced that new data on OJEMDA™ (tovorafenib) will be presented at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), taking place November 19-23, 2025. The upcoming oral presentation will feature updated results from the registrational Phase 2 FIREFLY-1 trial, evaluating tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma (pLGG) with a known activating BRAF alteration. The presentation will include more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data. The results will be delivered by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572050-en) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}